DENTSPLY SIRONA Inc. (XRAY) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 31 analysts29.0% Below Target
XRAY trades 29.0% below Wall Street's consensus target of $13.33.
Current Price$10.33
Average Target$13.33
Target
Current
Low$9.00
Median$14.00
High$17.00
Analyst Target Range
Forward P/E7.3x
(Value)
PEG Ratio—
Implied Growth+145.2%
(High Growth)
Analyst Spread60.0%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes XRAY achieves its forward estimates and maintains a stable P/E multiple of 7.3x. This scenario reflects the blended consensus of 31 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
XRAY Price Target Analysis
Updated June 22, 2026As of June 22, 2026, DENTSPLY SIRONA Inc. (XRAY) has a Wall Street consensus price target of $13.33, based on estimates from 31 covering analysts. With the stock currently trading at $10.33, this represents a potential upside of +29.0%. The company has a market capitalization of $2.07B.
Analyst price targets range from a low of $9.00 to a high of $17.00, representing a 60% spread in expectations. The median target of $14.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 12 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, XRAY trades at a trailing P/E of -3.4x and forward P/E of 7.3x. Analysts expect EPS to grow +145.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+36.0%
Industry Consensus
Avg Forward P/E
92.7x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ALGNAlign Technology, Inc. | $13.0B | $182.08 | $203.60 | +11.8% | Buy | 16.0x | 33 |
 HSICHenry Schein, Inc. | $9.2B | $79.92 | $87.43 | +9.4% | Buy | 14.9x | 33 |
 NVSTEnvista Holdings Corp | $4.2B | $25.91 | $28.33 | +9.3% | Hold | 18.1x | 19 |
 MMSIMerit Medical Systems, Inc. | $4.0B | $67.22 | $94.20 | +40.1% | Buy | 16.5x | 14 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 CNMDCONMED Corporation | $1.0B | $32.58 | $78.00 | +139.4% | Hold | 7.5x | 21 |
 ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
 SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
 ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
 IDXXIDEXX Laboratories, Inc. | $44.6B | $562.09 | $747.50 | +33.0% | Buy | 38.3x | 22 |
XRAY — Frequently Asked Questions
Quick answers to the most common questions about buying XRAY stock.
What is the XRAY stock price target for 2026?
The consensus Wall Street price target for XRAY is $13.33, representing 29.0% upside from the current price of $10.33. With 31 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is XRAY a buy, sell, or hold?
XRAY has a consensus rating of "Hold" based on 31 Wall Street analysts. The rating breakdown is mixed, with 18 Hold ratings making up the largest segment. The consensus 12-month price target of $13.33 implies 29.0% upside from current levels.
Is XRAY stock overvalued or undervalued?
With a forward P/E of 7.2767x, XRAY trades at a relatively low valuation. The consensus target of $13.33 implies 29.0% appreciation, suggesting meaningful undervaluation.
How high can XRAY stock go?
The most bullish Wall Street analyst has a price target of $17 for XRAY, while the most conservative target is $9. The consensus of $13.33 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover XRAY stock?
XRAY is heavily covered by Wall Street, with 31 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 18 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the XRAY stock forecast?
The 12-month XRAY stock forecast based on 31 Wall Street analysts shows a consensus price target of $13.33, with estimates ranging from $9 (bear case) to $17 (bull case). The median consensus rating is "Hold".
What is XRAY's forward P/E ratio?
XRAY trades at a forward P/E ratio of 7.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy XRAY stock?
Wall Street analysts are very optimistic on XRAY, with a "Hold" consensus rating and $13.33 price target (29.0% upside). 12 of 31 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do XRAY price targets vary so much?
XRAY analyst price targets range from $9 to $17, a 60% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13.33 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare